IL37 and arthritic joint disease: In particular, anti-IL-12 (ABT-874), anti-IL-15 (HuMax-IL15), anti-IL-18, ustekinumab (human monoclonal anti-IL-12/23 p40 antibody) and guselkumab (human monoclonal anti-IL-23 antibody) have shown promising results in murine models of arthritis and other rheumatoid diseases which are currently under further investigation [149,150,151,152].